


cyclo(RLsKDK)

Cat. No.:	HY-P1676
CAS No.:	1975145-82-4
Molecular Formula:	C ₃₁ H ₅₇ N ₁₁ O ₉
Molecular Weight:	727.85
Sequence:	Cyclo(Arg-Leu-[d-Ser]-Lys-Asp-Lys)
Sequence Shortening:	Cyclo(RL-[d-Ser]-KDK)
Target:	MMP
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	cyclo(RLsKDK) (BK-1361) is a specific inhibitor of metalloproteinase ADAM8 with an IC ₅₀ value of 182 nM. cyclo(RLsKDK) has potential applications in inflammatory diseases and cancer ^[1] .								
In Vitro	<p>cyclo(RLsKDK) promotes ADAM8 activation and CD23 shedding with IC₅₀ values of 120 nM and 182 nM, respectively^[2].</p> <p>cyclo(RLsKDK) (200 nM; 0-120 h) increases activity of pro-ADAM8^[2].</p> <p>cyclo(RLsKDK) (200 nM and 500 nM; 12 h) promotes the growth of Panc1_ctrl and Panc1_A8 cells^[2].</p> <p>cyclo(RLsKDK) (500 nM) causes ERK1/2 phosphorylation in Panc1_ctrl and Panc1_A8 cells^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Invasion Assay^[2]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Panc1_A8 cells.</td> </tr> <tr> <td>Concentration:</td> <td>10, 100 and 1,000 nM.</td> </tr> <tr> <td>Incubation Time:</td> <td>6 h.</td> </tr> <tr> <td>Result:</td> <td>Reduced cell invasion with dose-dependent manner.</td> </tr> </table>	Cell Line:	Panc1_A8 cells.	Concentration:	10, 100 and 1,000 nM.	Incubation Time:	6 h.	Result:	Reduced cell invasion with dose-dependent manner.
Cell Line:	Panc1_A8 cells.								
Concentration:	10, 100 and 1,000 nM.								
Incubation Time:	6 h.								
Result:	Reduced cell invasion with dose-dependent manner.								
In Vivo	<p>cyclo(RLsKDK) (10 µg/g; i.p.; once weekly for 4 weeks) significantly reduces tumour load in mice which implant Panc1_ctrl or Panc1_A8 cells. cyclo(RLsKDK) improves the survival rate of pancreatic ductal adenocarcinoma (PDAC) mice, reduces soluble ADAM8 (sADAM8) content, pERK1/2 activation, and PDAC metastasis in the liver and lungs of PDAC mice^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								

REFERENCES

[1]. Yim V, et al. Synthesis and biological evaluation of analogues of the potent ADAM8 inhibitor cyclo(RLsKDK) for the treatment of inflammatory diseases and cancer metastasis. *Bioorg Med Chem*. 2016 Sep 15;24(18):4032-4037.

[2]. Schlomann U, et al. ADAM8 as a drug target in pancreatic cancer. *Nat Commun*. 2015 Jan 28;6:6175.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA